Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 223-233 http://medscipublisher.com/index.php/cge 231 development of targeted therapies based on VHL mutation status are expected to enhance the accuracy of RCC diagnosis and improve treatment outcomes. Continued research in these areas will be crucial for translating these advancements into clinical practice. 7 Concluding Remarks The von Hippel-Lindau (VHL) gene plays a critical role in the pathogenesis of clear-cell renal cell carcinoma (ccRCC). Germline mutations in VHL cause von Hippel-Lindau disease, which is associated with a predisposition to various tumors, including ccRCC. In sporadic cases of ccRCC, VHL is frequently inactivated through mutations, promoter hypermethylation, or loss of heterozygosity. The VHL protein (pVHL) is essential for the degradation of hypoxia-inducible factors (HIFs), and its loss leads to the overexpression of HIF target genes, promoting tumorigenesis. Despite the high prevalence of VHL alterations in ccRCC, their prognostic and predictive value remains controversial, with some studies indicating no significant association with clinical outcomes, while others suggest a potential role in prognosis and treatment response. The identification of VHL gene alterations has significant implications for the diagnosis and management of ccRCC. The presence of VHL mutations or hypermethylation can serve as a diagnostic marker for ccRCC, aiding in the differentiation from other renal cancer subtypes. Furthermore, understanding the VHL-HIF pathway has led to the development of targeted therapies, such as sunitinib, sorafenib, and bevacizumab, which have shown efficacy in treating ccRCC by inhibiting downstream targets of the VHL/HIF pathway. However, the prognostic utility of VHL alterations remains uncertain, with some studies suggesting that VHL mutations are associated with better survival outcomes in certain patient subgroups, while others find no significant correlation. Future research should focus on elucidating the precise role of VHL alterations in ccRCC prognosis and treatment response. Prospective clinical trials should include the assessment of VHL status to determine its true utility as a prognostic and predictive marker. Additionally, further investigation into the molecular mechanisms downstream of VHL loss, such as the role of HIF-2α and other signaling pathways, could uncover new therapeutic targets. The development of novel therapies targeting these pathways holds promise for improving outcomes in patients with ccRCC. Integrating genetic and epigenetic analyses of VHL with other molecular markers may provide a more comprehensive understanding of ccRCC biology and lead to personalized treatment strategies. Acknowledgments The authors extend sincere thanks to two anonymous peer reviewers for their feedback on the manuscript. Conflict of Interest Disclosure The authors affirm that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Algaba F., Akaza H., López-Beltran A., Martignoni G., Moch H., Montironi R., and Reuter V., 2011, Current pathology keys of renal cell carcinoma, European Urology, 60(4): 634-643. https://doi.org/10.1016/j.eururo.2011.06.047 Ashida S., Furihata M., Tanimura M., Sugita O., Yamashita M., Miura T., Moriyama M., and Shuin T., 2003, Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status, The Journal of Urology, 169(6): 2089-2093. https://doi.org/10.1097/01.ju.0000063589.52935.84 Banks R., Tirukonda P., Taylor C., Hornigold N., Astuti D., Cohen D., Maher E., Stanley A., Harnden P., Joyce A., Knowles M., and Selby P., 2006, Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer, Cancer Research, 66(4): 2000-2011. https://doi.org/10.1158/0008-5472.CAN-05-3074 Brauch H., Weirich G., Brieger J., Glavač D., Rödl H., Eichinger M., Feurer M., Weidt E., Puranakanitstha C., Neuhaus C., Pomer S., Brenner W., Schirmacher P., Störkel S., Rotter M., Mas̆era A., Gugeler N., and Decker H., 2000, VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation, Cancer Research, 60(7): 1942-1948. Calzada M., Esteban M., Feijóo-Cuaresma M., Castellanos M., Naranjo-Suarez S., Temes E., Méndez F., Yañez‐Mó M., Ohh M., and Landazuri M., 2006, von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms, Cancer research, 66(3): 1553-1560. https://doi.org/10.1158/0008-5472.CAN-05-3236
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==